Detection of Immunotoxic Gluten Peptides in Feces

University of Seville53 enrolled

Overview

The purpose of this study is to monitor of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.

Certain immunotoxic peptides from gluten are resistant to gastrointestinal digestion and can interact with celiac patient factors to trigger immunological response. Gluten-free diet (GFD) is the only effective treatment for celiac disease (CD) and its compliance should be monitored to avoid accumulative damage. However, practical methods to monitor diet compliance and to detect the origin of an outbreak of celiac clinical symptoms are not available. This study assesses the capacity to determine the gluten ingestion, and to monitor the GFD compliance in celiac patients by detection of gluten and gliadin 33-mer equivalent peptidic epitopes in human feces.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Celiac Disease

Interventions

Detection of gluten in fecesOTHER

Detection of Gluten in Feces

Eligibility

Sex: ALLMin age: 1 YearMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Celiac patient * 1-12 years old * Written informed consent Exclusion Criteria: * Known inflammatory bowel diseases * Participation in any other studies involving investigational concomitantly or within two weeks prior to entry into the study and during the course of the study

Locations (1)

Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville

Seville, Seville, Spain

Outcomes

Primary Outcomes

Monitoring of gluten-free diet compliance in celiac patients

Usual gluten diet for celiac (home diet not modified for this trial)

Time frame: April-July 2011 (3 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.